GSK’s ViiV secured FDA approval for Dovato after submitting a marketing application with a priority review voucher (PRV) last October. The drug is used to treat HIV.
The Dovato regimen includes an integrase inhibitor, dolutegrevir. Integrase inhibitors work against HIV’s integrase protein, blocking its ability to integrate its genetic code into human cells.